New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
12:06 EDTTSRO, FPRXFive Prime could be close to collaboration deal, says Wells Fargo
Wells Fargo says that after speaking to management, it believes Five Prime Therapeutics (FPRX) may be close to finalizing a collaboration deal with a pharma company relating to its preclinical immunooncology targets. Wells expects a near-term partnership to drive shares of Five Prime higher, and notes TESARO (TRSO) is up around 30% today following its collaboration announcement.
News For FPRX;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
09:00 EDTFPRXBristol-Myers, Five Prime announce clinical collaboration for Opdivo, FPA008
Subscribe for More Information
November 20, 2014
07:51 EDTTSROTESARO, Myriad Genetics announce companion diagnostics collaboration
Subscribe for More Information
November 19, 2014
07:09 EDTTSROJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 17, 2014
16:54 EDTFPRXFive Prime initiates dosing of RA patients in FPA008 Phase 1 clinical trial
Five Prime Therapeutics discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing of rheumatoid arthritis, or RA, patients in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor, or CSF1R. FPA008 is being developed as a potential treatment for RA and solid tumors. FPA008 has two modes of action in RA, blocking the production of multiple inflammatory cytokines and directly inhibiting the activity of osteoclasts, thus preventing bone erosion.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use